Home > Insider Trading > Filing (0000950142-17-000550)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1461993	Cempra Inc.	CEMP	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1120478	Md A Dov Goldstein	888 7Th Avenue 12Th Floor New York NY 10106		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2017-03-07	50,100	$3.53	99,900	No	4	S	Indirect	By Aisling Capital II, LP
Common Stock	Disposition	2017-03-08	99,900	$3.57	0	No	4	S	Indirect	By Aisling Capital II, LP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Aisling Capital II, LP
No	4	S	Indirect	By Aisling Capital II, LP

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	95	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.500 to $3.575, inclusive. The reporting person undertakes to provide to Cempra, Inc., any security holder of Cempra, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.500 to $3.575, inclusive. The reporting person undertakes to provide to Cempra, Inc., any security holder of Cempra, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
The reportable securities are owned directly by Aisling Capital II, LP ("Aisling"), and held indirectly by Aisling GP, as general partner of Aisling, and Aisling Capital Partners, LLC, as general partner of Aisling GP. Dr. Goldstein is a member of the investment committee of Aisling. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.